Loading...
BHVN logo

Biohaven Ltd.NYSE:BHVN Stock Report

Market Cap US$2.2b
Share Price
n/a
1Y-8.6%
7D0.7%
1D-1.4%
Portfolio Value
​
View

Biohaven Ltd.

NYSE:BHVN Stock Report

Market Cap: US$2.2b

Biohaven (BHVN) Stock Overview

A biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. More details

BHVN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Trading at 73.1% below our estimate of its fair value

Revenue is forecast to grow 71.6% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

BHVN Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW478,064 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
478,064 investors already sharing narratives
View all narratives

Biohaven Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biohaven
Historical stock prices
Current Share PriceUS$14.64
52 Week HighUS$18.57
52 Week LowUS$7.48
Beta3.16
1 Month Change-5.18%
3 Month Change74.49%
1 Year Change-8.56%
3 Year Change-24.77%
5 Year Changen/a
Change since IPO100.55%

Recent News & Updates

Seeking Alpha • Jul 13

Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk

Summary Biohaven’s pipeline is now more focused after having to narrow down its R&D efforts to other assets. Today, I think opakalim’s pivotal epilepsy readout is probably the most important near-term catalyst that could validate their pipeline. They also have interesting, albeit early, positive findings with BHV-1300 and BHV-1400 for their degrader platform. Lastly, I believe taldefgrobep may become differentiated as a weight loss asset because it helps with fat loss while also preserving lean mass. However, I admit the stock has already rerated since my previous article on them. Yet, given their pipeline’s broader potential, I still lean bullish on BHVN long term. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jul 13

Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk

Summary Biohaven’s pipeline is now more focused after having to narrow down its R&D efforts to other assets. Today, I think opakalim’s pivotal epilepsy readout is probably the most important near-term catalyst that could validate their pipeline. They also have interesting, albeit early, positive findings with BHV-1300 and BHV-1400 for their degrader platform. Lastly, I believe taldefgrobep may become differentiated as a weight loss asset because it helps with fat loss while also preserving lean mass. However, I admit the stock has already rerated since my previous article on them. Yet, given their pipeline’s broader potential, I still lean bullish on BHVN long term. Read the full article on Seeking Alpha
Analysis Article • Jun 21

Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares

Biohaven (BHVN) drew investor attention after its stock rose 12.66% as the company outlined plans to start pivotal clinical studies for several cancer and autoimmune candidates in its pipeline. See our latest analysis for Biohaven. Looking beyond the latest jump, Biohaven’s share price return has been strong over shorter periods, with a 20.3% 7 day and 43.6% 30 day move. However, the 1 year total shareholder return declined 6.2%, which suggests recent momentum is rebuilding after a weaker...
Analysis Article • May 02

An Intrinsic Calculation For Biohaven Ltd. (NYSE:BHVN) Suggests It's 47% Undervalued

Key Insights Biohaven's estimated fair value is US$42.26 based on 2 Stage Free Cash Flow to Equity Current share price...
Seeking Alpha • Feb 28

Biohaven's Exciting Year Of Catalysts

Summary Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial upside remains due to Biohaven's promising later-stage clinical assets with key catalysts expected in 2025. The investment thesis hinges on the potential success of these clinical assets, which could drive further valuation growth. The current valuation rise is justified by the strategic leadership and promising pipeline, suggesting continued growth potential. Read the full article on Seeking Alpha
Seeking Alpha • Feb 11

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues

Summary Biohaven's pipeline is broad with multiple late stage molecules. Analysis based on Biohaven's 01/2025 J.P. Morgan Healthcare Conference Highlights and Presentation, Q3 2024 Earnings Release, and  10-Q. Biohaven's lead product's NDA is under review by the FDA. Article concludes with a "Hold" rating based on its hefty market cap and uncertain prospects. Read the full article on Seeking Alpha
Seeking Alpha • Nov 29

Biohaven's Revenue Path: SCA And Obesity Therapies

Summary Biohaven’s pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion globally. Taldefgrobep Alfa, under investigation for SMA and obesity, demonstrated subgroup-specific motor function improvements and favorable safety in Phase 3 trials. Despite a $250 million equity raise, BHVN's cash burn of $141.9 million per quarter poses financial sustainability risks, making commercialization critical. Therefore, BHVN's positive clinical progress, high cash burn, and frequent equity raises make it a speculative buy. Read the full article on Seeking Alpha
Seeking Alpha • Oct 11

Biohaven: A Complicated Tale

Summary Biohaven's stock has surged despite past setbacks, driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies. The company is advancing a diverse pipeline, including myostatin inhibitor taldefgrobep alfa for SMA and obesity, and Kv7 ion channel activator BHV-7000 for epilepsy. Biohaven's strategic capital raises, and positive clinical data have rallied its stock, but future dilution risks remain if trials disappoint. An updated analysis of Biohaven follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Sep 23

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Summary Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression over 3 years. With positive data on hand from the phase 3 study using troriluzole for patients with spinocerebellar ataxia, an NDA submission is planned for Q4 of 2024. Troriluzole is also being explored for patients with obsessive compulsive disorder in two phase 3 studies; Data from these studies are expected before the end of 2024 and the 1st half of 2025. Topline data from the phase 3 study using Taldefgrobep Alfa for SMA is expected 2nd half of 2024; the Drug is also expected to be initiated in a phase 2 study for obesity as well. Read the full article on Seeking Alpha
Seeking Alpha • Jul 26

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Summary Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032. Preclinical model testing showed that myostatin inhibitor taldefgrobep alfa + GLP-1 inhibitor was able to show greater reductions in body weight and fat loss, compared to that of GLP-1 alone. It is expected that the global obesity treatment market size is expected to be worth $38 billion by 2032. Read the full article on Seeking Alpha
Seeking Alpha • May 18

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Summary Biohaven Ltd. is a spinout of Biohaven Pharmaceutical, focusing on developing drugs in the life sciences field. BHVN has three Phase 3 drug candidates: troriluzole for OCD, taldefgrobep alfa for SMA, and BHV-7000 for epilepsy and bipolar disorder. Also, the company has a diverse pipeline of drugs in various stages, including those targeting neurology, immunology, and oncology. Upcoming catalysts include FDA approval decisions and clinical trial results, which could significantly impact BHVN's stock performance. Despite the short cash runway, BHVN is a 'buy' due to its promising drug candidates and upcoming catalysts. Read the full article on Seeking Alpha
Analysis Article • Apr 06

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. By way of example, Biohaven...
Analysis Article • Mar 01

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$49.64 With US$48.14 share...
Seeking Alpha • Feb 28

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Summary Biohaven's stock rose 130% post "Sell" recommendation; overlooked assets like BHV-7000 suggest early growth stages remain. The company's pipeline, particularly their Kv7 activators and IgG degrader, show promise and have blockbuster potential in treating epilepsy and immune-mediated diseases. Financially, with a cash runway extended to 20.7 months post-offering, Biohaven shows robust short-term health. Upgrading BHVN to "Buy" due to pipeline promise and market potential, despite competition risks and high cash burn. Read the full article on Seeking Alpha
Seeking Alpha • Dec 08

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Summary Today, we circle back on a promising biopharma concern called Biohaven Ltd., whose shares have had a significant rally in recent months. The company has a diverse pipeline of therapies for neurological and neuropsychiatric diseases, with a mixture of early and late-stage candidates. A portfolio review and analysis around Biohaven follow in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Dec 04

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, Biohaven...
Seeking Alpha • Sep 27

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Summary Biohaven's stock surged nearly 30% following updates on its preclinical asset, the IgA degrader BHV-1300. The company's stock has risen more than 270% since its spinout from parent company Biohaven Pharmaceutical. Biohaven's preclinical pipeline includes assets targeting a wide range of central nervous system conditions and autoimmune diseases. As intriguing as today's data was, it does not necessarily support the buy case for Biohaven. Arguably, the data may have been released in response to promising IgG removal data released by Immunovant earlier this week. Time will tell, but I'm on the sidelines. Read the full article on Seeking Alpha
Seeking Alpha • Aug 28

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Summary Biohaven faces FDA rejection for troriluzole; explores further discussions and potential subgroup focus. Despite FDA setback, Biohaven maintains a strong cash position, diversified pipeline, and ongoing R&D efforts. Given current uncertainties and valuation, I recommend a "Sell" stance on Biohaven's stock. Read the full article on Seeking Alpha

Shareholder Returns

BHVNUS BiotechsUS Market
7D0.7%0.5%0.6%
1Y-8.6%35.8%20.1%

Return vs Industry: BHVN underperformed the US Biotechs industry which returned 35.8% over the past year.

Return vs Market: BHVN underperformed the US Market which returned 20.1% over the past year.

Price Volatility

Is BHVN's price volatile compared to industry and market?
BHVN volatility
BHVN Average Weekly Movement11.3%
Biotechs Industry Average Movement9.9%
Market Average Movement7.1%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: BHVN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BHVN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2022274Vlad Coricwww.biohaven.com

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.

Biohaven Ltd. Fundamentals Summary

How do Biohaven's earnings and revenue compare to its market cap?
BHVN fundamental statistics
Market capUS$2.21b
Earnings (TTM)-US$586.84m
Revenue (TTM)n/a
0.0x
P/S Ratio
-3.8x
P/E Ratio

Is BHVN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BHVN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$586.84m
Earnings-US$586.84m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-3.89
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio2,123.1%

How did BHVN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/17 17:38
End of Day Share Price 2026/08/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biohaven Ltd. is covered by 23 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
William PickeringBernstein
Dina RamadaneBofA Global Research